Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. LIDDS AB (publ)
  6. News
  7. Summary
    LIDDS   SE0001958612

LIDDS AB (PUBL)

(LIDDS)
  Report
Delayed Nasdaq Stockholm  -  03:53 2022-12-07 am EST
2.850 SEK   -4.36%
11/30Nomination Committee appointed for the Annual General Meeting 2023 in LIDDS
AQ
11/28LIDDS AB (publ) Interim Report January – September 2022
AQ
11/28LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

LIDDS presents at investor events

11/24/2022 | 08:46am EST

UPPSALA, SWEDEN - LIDDS AB (publ) announces today that the company’s CEO Anders Månsson will participate at Stora Aktiedagen and BioStock Life Science Fall Summit.

LIDDS’ CEO Anders Månsson presents the company at Stora Aktiedagen in Stockholm on 28 November at 08.00. Stora Aktiedagen is arranged by Aktiespararna and is webcasted live and on demand on Aktiespararna’s youtube channel and aktiespararna.se.

LIDDS’ CEO Anders Månsson also participates in BioStock Life Science Fall Summit in Lund where he presents the company on 30 November at 09.05.

Both presentations will be available on the company website www.liddspharma.com after the events.

© Modular Finance, source Nordic Press Releases

All news about LIDDS AB (PUBL)
11/30Nomination Committee appointed for the Annual General Meeting 2023 in LIDDS
AQ
11/28LIDDS AB (publ) Interim Report January – September 2022
AQ
11/28LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September..
CI
11/24LIDDS presents at investor events
AQ
11/04Interview with LIDDS' CEO Anders Månsson published on the company's website
AQ
10/18LIDDS participates in partnering events
AQ
09/26LIDDS participates in Nordic Life Science Days 2022
AQ
08/25LIDDS AB (publ) Interim Report January – June 2022
AQ
08/25LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, ..
CI
07/15LIDDS AB (publ) announces the appointment of Anders Månsson as CEO
AQ
More news
Financials
Sales 2021 3,55 M 0,34 M 0,34 M
Net income 2021 -37,3 M -3,59 M -3,59 M
Net cash 2021 34,0 M 3,28 M 3,28 M
P/E ratio 2021 -8,20x
Yield 2021 -
Capitalization 104 M 9,97 M 9,97 M
EV / Sales 2020 1 164x
EV / Sales 2021 81,8x
Nbr of Employees 7
Free-Float 61,3%
Chart LIDDS AB (PUBL)
Duration : Period :
LIDDS AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Anders Mňnsson Chief Executive Officer
Jenni Bj÷rnulfson Chief Financial Officer
Jan Birger Fredrik T÷rnell Chairman
Stefan GrudÚn Director-Pharmaceutical Research & Development
Johan Georg Harmenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
LIDDS AB (PUBL)-68.80%10
VERTEX PHARMACEUTICALS44.63%80 039
REGENERON PHARMACEUTICALS, INC.19.62%79 831
BIONTECH SE-37.31%39 277
WUXI APPTEC CO., LTD.-34.04%32 589
GENMAB A/S23.38%29 957